白细胞ADAM10与ADAM17调控细菌性和病毒性肺炎疾病严重程度及全身结局
本研究结合COVID-19与细菌性肺炎患者样本、条件性敲除小鼠模型及细胞实验,系统表征白细胞及循环外泌体上ADAM10和ADAM17在病毒性和细菌性肺炎中的作用。住院患者外泌体ADAM10和ADAM17活性呈严重程度依赖性升高,并可导致心肌细胞和内皮屏障病理生理改变;小鼠模型中白细胞贡献该外泌体蛋白酶活性升高,ADAM10促进促炎反应而ADAM17似抑制初始炎症。
要点
- 住院COVID-19和细菌性肺炎患者外泌体ADAM10/ADAM17活性随疾病严重程度升高。
- 患者外泌体可导致心肌细胞和内皮屏障病理生理改变。
- 小鼠模型中白细胞贡献外泌体蛋白酶活性升高,ADAM10促炎而ADAM17抑炎。
核心结论
- 白细胞ADAM10和ADAM17及其经外泌体释放可能是细菌性和病毒性肺炎的相关调控要素,外泌体可能促进疾病进展和全身炎症反应。
研究设计与样本
- 研究结合COVID-19和细菌性肺炎患者样本分析、白细胞条件性敲除ADAM10或ADAM17的动物体内实验及细胞培养机制研究。
主要发现
- 住院细菌性肺炎和COVID-19患者外泌体ADAM10和ADAM17活性呈严重程度依赖性增加。
- 这些外泌体引起心肌细胞和内皮屏障的病理生理改变。
- 临床前小鼠肺炎模型中,白细胞贡献外泌体蛋白水解活性增加。
- 肺局部环境中ADAM10协调促炎反应,包括M1巨噬细胞极化、活性氧生成增加、细胞因子释放、组织损伤和水肿形成。
- ADAM17似将初始炎症反应抑制至抗感染、活性氧平衡水平。
临床怎么用
- ADAM10和ADAM17的诊断、预后和治疗价值需在进一步临床前和转化研究中评估。
局限性
- 需进一步临床前和转化研究评估ADAM10和ADAM17的诊断、预后和治疗价值,并探讨免疫反应和外泌体作为载体在局部及预防全身效应中的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumonia caused by viral or bacterial pathogens such as severe acute respiratory syndrome coronavirus 2 or Pseudomonas aeruginosa may result in life-threatening disease with a strong contribution of protease dysregulation. The present study aimed to systematically characterise the contribution of ADAM10 and ADAM17 on leukocytes and circulating exosomes to viral and bacterial pneumonia. METHODS: The analysis of coronavirus disease 2019 (COVID-19) and bacterial pneumonia patient samples was combined with in vivo experiments in conditional knockout animals lacking either ADAM10 or ADAM17 in leukocytes and cell culture experiments for mechanistic studies. RESULTS: Hospitalised bacterial pneumonia and COVID-19 patients displayed a severity dependent increase of ADAM10 and ADAM17 activity on exosomes. These exosomes caused pathophysiological changes of cardiomyocytes and the endothelial barrier. In a pre-clinical murine pneumonia model, we observed that leukocytes contributed to this increase in exosomal proteolytic activity. In the local environment of the lung, ADAM10 orchestrated a pro-inflammatory response with M1 macrophage polarisation, increased reactive oxygen species (ROS) generation, cytokine release, tissue damage and oedema formation, whereas ADAM17 seemed to dampen the initial inflammatory response to an anti-infective, ROS-balanced level. CONCLUSION: Leukocytic ADAM10 and ADAM17 and their release on exosomes may constitute relevant regulatory elements in bacterial and viral pneumonia, with a potential contribution of exosomes to disease progression and systemic inflammatory responses. Therefore, the diagnostic, prognostic and therapeutic value of ADAM10 and ADAM17 should be evaluated in further preclinical and translational studies, addressing the changes of the immune response and exosomes as cargo vehicles both at local site and for the prevention of systemic effects.
引用
- Aljohmani A, Herr C, Witzenrath M, et al. Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia. Eur Respir J. 2026. PMID: 41198388. doi:10.1183/13993003.02060-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。